Pomerantz Law Firm Launches Investigation into Celcuity Inc. for Potential Investor Claims
Investors in Celcuity Inc. (NASDAQ: CELC) may want to pay attention as Pomerantz LLP initiates an investigation into potential securities fraud following the company's recent press release. The specifics of this investigation hint at the possibility that Celcuity's management may have misled shareholders regarding business operations, particularly about the anticipated launch of their breast cancer therapy, Revtorpyk, formerly known as gedatolisib.
On July 14, 2026, Celcuity revealed that it had received approval from the U.S. Food and Drug Administration (FDA) for Revtorpyk. However, the anticipated commercial launch was pushed to late Q3 2026, which raised eyebrows among analysts. Experts had previously speculated that the launch would align much better with their expectations based on earlier communications from Celcuity. Stifel analyst Stephen Wiley remarked, 'The late Q3 2026 launch seems somewhat extended.' In a similar vein, Leerink analyst Andrew Berens pointed out, 'While the approval was largely expected, we did not anticipate a Q3 launch date given prior commentary on launch readiness.'
Following the announcement, Celcuity's stock price took a significant hit, plummeting by $19.54, or 17.6%, closing at $91.51 on July 15, 2026. This abrupt decline has prompted investors to question the transparency and communication policies of Celcuity’s leadership. According to Pomerantz LLP, whose history in securities and corporate law is well established, investors who believe they may have been misled into harmful financial decisions due to these developments are encouraged to contact them directly.
Founded by Abraham L. Pomerantz, who is recognized as a pioneer in securities class actions, the law firm continues to advocate for those harmed by corporate misconduct. Over its 85-year history, Pomerantz has successfully fought for the rights of shareholders, recovering substantial compensation for victims of fraud.
With the firm having offices in major cities such as New York, Chicago, and Los Angeles, they are well positioned to support clients across various regions. The ongoing investigation aims to determine whether the company's officers or directors engaged in any unlawful business practices that could affect investor rights.
For investors seeking more information or wishing to participate in the ongoing investigation, they can reach out to Danielle Peyton, of Pomerantz LLP, through email or by phone as noted in the firm’s recent announcement.
As developments unfold around Celcuity’s situation, investors are encouraged to stay informed about their rights and the implications of the firm's actions. This event underscores the importance of vigilance in the stock market and highlights the role that firms like Pomerantz play in safeguarding investor interests against potential misrepresentation and fraud.
On July 14, 2026, Celcuity revealed that it had received approval from the U.S. Food and Drug Administration (FDA) for Revtorpyk. However, the anticipated commercial launch was pushed to late Q3 2026, which raised eyebrows among analysts. Experts had previously speculated that the launch would align much better with their expectations based on earlier communications from Celcuity. Stifel analyst Stephen Wiley remarked, 'The late Q3 2026 launch seems somewhat extended.' In a similar vein, Leerink analyst Andrew Berens pointed out, 'While the approval was largely expected, we did not anticipate a Q3 launch date given prior commentary on launch readiness.'
Following the announcement, Celcuity's stock price took a significant hit, plummeting by $19.54, or 17.6%, closing at $91.51 on July 15, 2026. This abrupt decline has prompted investors to question the transparency and communication policies of Celcuity’s leadership. According to Pomerantz LLP, whose history in securities and corporate law is well established, investors who believe they may have been misled into harmful financial decisions due to these developments are encouraged to contact them directly.
Founded by Abraham L. Pomerantz, who is recognized as a pioneer in securities class actions, the law firm continues to advocate for those harmed by corporate misconduct. Over its 85-year history, Pomerantz has successfully fought for the rights of shareholders, recovering substantial compensation for victims of fraud.
With the firm having offices in major cities such as New York, Chicago, and Los Angeles, they are well positioned to support clients across various regions. The ongoing investigation aims to determine whether the company's officers or directors engaged in any unlawful business practices that could affect investor rights.
For investors seeking more information or wishing to participate in the ongoing investigation, they can reach out to Danielle Peyton, of Pomerantz LLP, through email or by phone as noted in the firm’s recent announcement.
As developments unfold around Celcuity’s situation, investors are encouraged to stay informed about their rights and the implications of the firm's actions. This event underscores the importance of vigilance in the stock market and highlights the role that firms like Pomerantz play in safeguarding investor interests against potential misrepresentation and fraud.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.